APA (7th ed.) Citation

F, A., J, T., A, C., L, P., J, A., E, R., . . . J, B. (2011). A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 17(19), 6304. https://doi.org/10.1158/1078-0432.CCR-10-3336

Chicago Style (17th ed.) Citation

F, Atzori, et al. "A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 17, no. 19 (2011): 6304. https://doi.org/10.1158/1078-0432.CCR-10-3336.

MLA (9th ed.) Citation

F, Atzori, et al. "A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 17, no. 19, 2011, p. 6304, https://doi.org/10.1158/1078-0432.CCR-10-3336.